The aim of this study is to describe the real clinical use of Dalbavancin in Spain between January 2018 and December 2019.
Dalbavancin is a new lipoglycopeptide approved for the treatment of ABSSSIs (Acute Bacterial Skin and Skin-Structure Infections) with activity against Gram-positive pathogens, including MRSA. Dalbavancin has unique pharmacokinetics properties, with a terminal half-life of 14.4 days, permitting a single intravenous dosing. Dalbavancin has shown a favourable efficacy and safety profile in patients with ABSSSI in randomized controlled trials. However, information regarding daily clinical practice is limited. The main objective of this study is to describe the real clinical practice with Dalbavancin in Spain.
Study Type
OBSERVATIONAL
Enrollment
187
Hospital Universitario A Coruña
A Coruña, Spain
Hospital Universitari Vall d'Hebrón
Barcelona, Spain
Hospital Clínic Barcelona
Barcelona, Spain
Hospital Universitario Virgen de las Nieves
Granada, Spain
Demographic and clinical characteristics of patients treated with dalbavancin
To describe the demographic and clinical characteristics of patients treated with dalbavancin (primary objective)
Time frame: patients treated with dalbavancin between January 2018 and December 2019
Variables related to dalbavancin treatment
To describe the demographic and clinical characteristics of patients treated with dalbavancin (primary objective)
Time frame: patients treated with dalbavancin between January 2018 and December 2019
Effectiveness/Clinical response
Clinical response (signs and symptoms) evaluated at the end of treatment
Time frame: From 48-72h after the end of treatment until 90 days after last dose of dalbavancin
Effectiveness/Relapse
Relapse (Yes/No)
Time frame: 90 days after after last dose of dalbavancin
Safety. Adverse events
Rate of adverse events Rate of treatment discontinuation due to Adverse events
Time frame: From first dose until 90 days after last dose of dalbavancin
Treatment compliance
Patient received the full dose of dalbavancin (Yes/No)
Time frame: : From first dose until 90 days after last dose of dalbavancin
Doctors opinion on infection management with dalbavancin (1)
Degree of physician satisfaction on management with dalbavancin: Dissatisfied, Little satisfied, Satisfied, Very satisfied
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universtario La Fe
Valencia, Spain
Time frame: From first dose until 90 days after last dose of dalbavancin
Doctors opinion on infection management with dalbavancin (2)
Physician assessment on potential reduction in the number of days of hospital stay (Yes/No)
Time frame: From first dose until 90 days after last dose of dalbavancin